Volume 30, Number 5—May 2024
Research
Cross-Sectional Study of Q Fever Seroprevalence among Blood Donors, Israel, 2021
Nesrin Ghanem-Zoubi1
, Yafit Atiya-Nasagi1, Evgeniy Stoyanov, Moran Szwarcwort, Basel Darawsha, Mical Paul, and Eilat Shinar
, Yafit Atiya-Nasagi1, Evgeniy Stoyanov, Moran Szwarcwort, Basel Darawsha, Mical Paul, and Eilat Shinar
Table 2
Crude prevalence of anti-Coxiella burnetti IgG in cohort groups in cross-sectional study of Q fever seroprevalence among blood donors, Israel, 2021
| Parameter | No. participants | No. seropositive (%) |
|---|---|---|
| Overall |
1,473 |
188 (12.7) |
| Sex | ||
| M | 859 | 128 (14.9) |
| F |
614 |
60 (9.8) |
| Age group, y | ||
| 18–30 y | 550 | 50 (9.0) |
| 31–50 y | 502 | 85 (16.9) |
| >50 y |
299 |
52 (17.4) |
| Geographic factors | ||
| Born in Israel | 1,205 | 153 (12.7) |
| Living in Jewish locality | 1,310 | 167 (12.7) |
| Living in Arab locality | 157 | 21 (13.4) |
| Rural | 372 | 38 (10.2) |
| Urban |
1,095 |
150 (13.7) |
| Socioeconomic status of residence localities | ||
| Low | 328 | 39 (11.9) |
| Middle | 714 | 94 (13.2) |
| High | 416 | 54 (13.0) |
1These authors contributed equally to this article.
Page created: March 07, 2024
Page updated: April 23, 2024
Page reviewed: April 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.